Hims & Hers Stock Soars 48% in a Week on RFK Jr.’s Peptide Promotion
Market reaction and momentum
The stock jumped as much as 11% on Monday. It has climbed roughly 125% from February lows after a prolonged downturn that began late 2025.
Online attention spiked for headlines such as “Hims & Hers Stock Soars 48% in a Week on RFK Jr.’s Peptide Promotion.” That search interest mirrored heightened investor focus.
Regulatory developments
On April 15, Health Secretary Robert F. Kennedy Jr. said the FDA will reassess peptide restrictions. The agency plans a July meeting to weigh loosening rules for certain peptides.
The FDA had limited 19 peptides in 2023 because of health concerns. Officials will evaluate removing 12 peptides from those limits.
RFK Jr.’s role
Robert F. Kennedy Jr. has publicly backed wider peptide access. He told listeners on Joe Rogan’s podcast in February that peptides helped him personally.
Hims & Hers strategy and shifts
Hims built its business on direct-to-consumer prescriptions. The company serves customers with hair loss, erectile dysfunction, mental health and skincare offerings.
Its breakout growth came when it sold compounded GLP-1 alternatives during 2024 shortages. Those shortages affected Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Financial and legal backdrop
Revenue rose 59% in 2025, reaching $2.35 billion. That expansion increased regulatory and legal exposure.
An April 2025 partnership with Novo Nordisk collapsed within two months. Novo accused Hims of promoting knockoff Wegovy alternatives, triggering lawsuits and FDA warnings.
In March, the companies reached a deal. Hims agreed to prioritize Novo’s branded GLP-1s, and Novo agreed to drop the lawsuit.
Peptide production and product plans
Hims bought a California-based peptide manufacturing site in February 2025. The purchase positions the company to scale peptide production if regulators permit.
Executives say the firm is building a peptide-based line. The product line sits inside a planned longevity specialty set to debut this year.
Industry context and risks
Novo Nordisk lost about $500 billion in market value from its 2024 peak. Competition from Eli Lilly and compounding pharmacies pressured prices and market share.
Peptides such as BPC-157, GHK-Cu and GLP analogs have become widespread online. Influencers, longevity clinics and gray-market sellers helped fuel demand.
Regulatory limbo and gray markets
Before the 2023 FDA limits, many peptides occupied a legal gray area. The restrictions clarified which compounds compounding pharmacies could make.
The rules also increased imports of unregulated products. Reports noted a rise in foreign-sourced “Chinese peptides” and use among young “looksmaxxers.”
Filmogaz.com will continue to monitor regulatory developments and company filings. The outcome of the FDA review could reshape telehealth offerings and market dynamics.
